Laura Stoppel

Laura Stoppel Ph.D., is an Analyst on the Investment Team at RA Capital Management. Laura’s primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Prior to this role, Laura was a Senior Associate on the Oncology, Ophthalmology, and Neurology Teams within the TechAtlas division of RA Capital, where she mapped competitive landscapes of drugs and medical devices for disease indications and capabilities, with a focus on hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura serves as a director on the board of Artiva Biotherapeutics as well as an observer on the board of Vor Biopharma. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.